Artelo Biosciences, Inc（ARTL）のニュースとイベントARTLArtelo Biosciences, Inc

Artelo Biosciences Files Patent Application for ART27.13 in Obesity Treatment

Artelo Biosciences announced the filing of a provisional patent application covering the use of ART27.13 for the treatment of obesity. The application covers ART27.13 both as a monotherapy and in combination with GLP-1 receptor agonists such as semaglutide, the active ingredient in Ozempic and Wegovy. The filing follows unexpected findings from Artelo's nonclinical DIO-2 study that point to a potentially broader role for ART27.13 in weight and metabolic regulation. The Company is disclosing additional findings from the study today, alongside results reported on September 16, 2026.

Artelo Biosciences ART27.13 Shows Significant Weight Loss Results

Artelo Biosciences announced results from a nonclinical study of ART27.13, its oral, once-daily, peripherally selective dual cannabinoid receptor agonist, in the diet-induced obesity model widely used to evaluate GLP-1 and other weight-loss medicines. In the study, ART27.13 administered alone produced weight loss comparable to semaglutide, and ART27.13 in combination with semaglutide approximately doubled the weight loss achieved with either agent alone. In obese mice fed a high-fat diet, ART27.13 as a monotherapy reduced body weight from baseline by approximately 20% over four weeks - essentially mirroring the weight-loss curve of semaglutide. Obese mice treated with both ART27.13 and semaglutide lost approximately 40% of their baseline body weight - twice the weight loss of either agent alone - bringing them to the body weight of lean, normal-weight animals. Fat loss was greater in the ART27.13 treated groups. Lean body mass and body fat were normalized to lean control animals by ART27.13 or semaglutide to similar extents, and the greatest effects were observed in the combination group of ART27.13 and semaglutide. ART27.13 had no effect on body weight, fat mass or lean mass in lean mice fed a standard diet. The weight-loss effect of ART27.13 appears to be specific to the obese state. Food consumption in treated obese animals declined initially and then recovered over the course of the study, while body weight remained at its reduced level. Other markers of metabolic dysregulation were favorable for ART27.13 monotherapy, with the greatest effects shown in the combination with semaglutide. The findings challenge a long-held assumption in obesity research. For more than two decades, the pharmaceutical industry's approach to cannabinoid receptors in obesity has focused on blocking the CB1 receptor with antagonists or inverse agonists. Full agonists such as ART27.13 which activate the receptors have largely been avoided. ART27.13 is a highly potent agonist of both the CB1 and CB2 receptors that is designed to act in the body's peripheral tissues while minimizing effects in the brain. Its ability to produce weight and fat loss in obese animals therefore represents a new and differentiated pharmacology in the field. The results are consistent with independent, peer-reviewed research showing that both THC and synthetic cannabinoid receptor agonists can reduce body weight and fat in obese animals while having no effect on body weight or metabolic parameters in lean animals. The Artelo data extend those observations to a clinical-stage, orally administered small molecule, with an effect size comparable to the leading GLP-1 medicine.

Artelo Biosciences Announces 1-for-9 Reverse Stock Split

Artelo Biosciences announced a 1-for-9 reverse stock split of the company's common stock. The company's common stock will begin trading on a split-adjusted basis on Nasdaq commencing at the market open on August 31. The reverse split is being effected in order to increase the price per share of the common stock to improve its marketability and liquidity.